🇺🇸 FDA
Patent

US 10723777

Peptide having anti-obesity and anti-diabetes efficacy and use thereof

granted A61KA61K38/00A61P

Quick answer

US patent 10723777 (Peptide having anti-obesity and anti-diabetes efficacy and use thereof) held by CAREGEN CO., LTD. expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
CAREGEN CO., LTD.
Grant date
Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61K, A61K38/00, A61P, A61P3/04, A61P3/10